ILARIS Novartis Pharmaceuticals Australia Pty Ltd
Product name
ILARIS
Accepted date
Jul-2024
Active ingredients
Canakinumab
Proposed indication
For the treatment of several autoinflammatory Periodic Fever Syndromes in adults, adolescents and children aged 2 years and older.
Application type
C (new indication)
Publication date
Jul-2024